Nagesh Mahanthappa

Scholar Rock, Inc. operates as a biotechnology company. It focuses on discovering and developing a novel class of biologic therapies that target supracellular activation of growth factors in the disease microenvironment. The company was founded by Timothy Springer and Leonard Zon and is headquartered in Cambridge, MA.

Part of Abbott Laboratories, TwistDx Ltd. is a British company that specializes in recombinase polymerase amplification technology. The private company is based in Maidenhead, UK. The company offers TwistAmp research kits for researchers to develop tests, assays, and kits relevant to their work in fields such as water testing, biodefense, food species verification, and clinical or veterinary diagnostics. The company can work with partners on specific assay development collaborations for research and commercial applications. The company offers devices and accessories for research and development use only. The company was founded in 2002 by Niall Armes, Derek Stemple, Nagesh K. Mahanthappa.

Casma Therapeutics, Inc. operates biotechnology company harnessing natural cellular process of autophagy to design new medicines. The company was founded by Cary Pfeffer and is headquartered in Cambridge, MA.

Camena Bioscience Ltd. is a British biotechnology company that produces long and complex synthetic genes. The company is based in Cambridge, UK. Camena Bioscience was founded in 2016 by Steve Harvey. Steve Harvey has been the CEO since 2016.

Exo Therapeutics, Inc. engages in production of drugs. It has developed a small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes (exo-sites) that are not evolutionarily conserved. The company was founded by David R. Liu and Alan Saghatelian and is headquartered in Boston, MA.

Kojin Therapeutics, Inc. operates as a small-molecule therapeutics company. It focuses on translating deep biological insight into the plasticity of human cell states to develop therapeutics for cancer, fibrosis, ischemia and immune modulation. The company was founded by Benjamin Cravatt, Stephanie K. Dougan and Stuart L.Schreiber and is headquartered in the United States.

Abata Therapeutics, Inc. is a biotech company based in Watertown, MA. Abata Therapeutics is focused on developing engineered Treg cell therapies for severe autoimmune and inflammatory diseases. The American company's lead programs are in ind-enabling studies for progressive multiple sclerosis and type 1 diabetes, both of which are tissue-specific autoimmune diseases with significant unmet needs. The company has developed a differentiated product engine to create tissue-specific, robust, and durable therapies. Abata Therapeutics was launched by Third Rock Ventures, with participation from a diverse syndicate of investors, including ElevateBio, Lightspeed Venture Partners, Invus, Samsara Biocapital, and the JDRF T1D Fund. The company was founded in 2021 by Richard Ransohoff and the CEO is Samantha Singer.